GAINESVILLE, Fla.--(BUSINESS WIRE)--U.S. Precision Medicine, Inc. (USPM), a biopharma company developing novel cancer therapeutics, today announced it will use state-of-the-art artificial intelligence (AI) technology to bolster independent research that has proven the company’s small molecule candidate is highly effective in killing breast cancer.
U.S. Precision Medicine’s new cancer drug candidate has demonstrated the ability to reduce tumor weight and volume by 85% in just 30 days of treatment with no toxicity. The findings were corroborated in the independent Investigational New Drug (IND) research with small animal studies required by the FDA. The company’s contract research organization currently is developing the dosing plan and expanding the research to include an additional 100 cancer types, for which patents or patents pending are held.
"Now that the validity of AI in pharmaceutical drug development is gaining traction, we plan to conduct a comparative study leveraging AI platforms in parallel with our ongoing IND research to prepare for human clinical trials," said Frederick Fey, co-founder and CEO of USPM.
“The drug candidate shows great promise as a treatment for most, if not all, solid tumor cancers, which account for approximately 90 percent of adult cancers and 30 percent of all pediatric cancers.”
The worldwide incidence of cancer continues to rise, with the American Cancer Society projecting a 77% increase in new cases by 2050 versus 2022 levels. Last year, there were approximately 20 million new cancer diagnoses and 9.7 million cancer deaths globally.
"Cancer represents a tremendous unmet medical need that is projected to reach $200 billion by 2025 for cancer drugs alone," said Christopher Fey, co-founder and COO of USPM. "My brother and I are passionate about turning cancer victims into survivors because our father passed away from colon cancer at age 29 when we were toddlers. We hope others will join us in improving outcomes for patients across all cancer types."
U.S. Precision Medicine, Inc. (USPM) is a biopharma company that identifies and validates promising, patented small molecule cancer drug candidates from academic institutions, with the goal of licensing them to pharmaceutical companies to improve patient outcomes. USPM confirms drug efficacy and advances candidates with the greatest potential through the FDA's Investigational New Drug process and Phase 1 clinical trials to build value ahead of potential partnering or M&A transactions.
For more information, please visit www.USPrecisionMedicine.com.
